Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)
Long Term Safety Study of Amifampridine Phosphate in Patients With MuSK Antibody Positive and AChR (Acetylcholine Receptor) Antibody Positive Myasthenia Gravis
Sponsor: Catalyst Pharmaceuticals, Inc.
Terminated
Lack of measure appropriate data (MG-ADL).
Other terminated trials from Catalyst Pharmaceuticals, Inc.
- Spinal Muscular Atrophy Type 3 · Phase PHASE2 · Sep 2021
- Methamphetamine Dependence · Phase PHASE2 · Nov 2009
More terminations from Catalyst Pharmaceuticals, Inc.
This PHASE3 trial investigates AChR Myasthenia Gravis and Myasthenia Gravis, MuSK and is currently terminated or withdrawn. Catalyst Pharmaceuticals, Inc. leads this study, which shows 12 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
May 2023 — Jun 2024 [monthly]
Active Not Recruiting PHASE3
-
Sep 2022 — May 2023 [monthly]
Active Not Recruiting PHASE3
▶ Show 7 earlier versions
-
Apr 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
-
Mar 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE3
-
Mar 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2019 — Mar 2020 [monthly]
Recruiting PHASE3
-
Mar 2019 — Sep 2019 [monthly]
Recruiting PHASE3
-
Aug 2018 — Mar 2019 [monthly]
Recruiting PHASE3
First recorded
Jun 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Catalyst Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .